{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-107408","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2022-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.117558+00:00","generated_at":"2026-06-23T04:28:21.066901+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Passage Bio appoints William Chou as CEO, replacing interim CEO Chip Cale","bullets":["William Chou appointed CEO and director effective October 10, 2022.","Edgar B. Cale resigned as interim CEO; continues as General Counsel and Corporate Secretary.","Dr. Chou receives $580k base salary, 55% target bonus, and $200k sign-on bonus with clawback.","Granted option to purchase 885,000 shares vesting over 4 years.","Severance includes 12 months base salary plus bonus on termination without cause."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-107408","json":"https://secwatch.observer/filing/0001104659-22-107408.json","markdown":"https://secwatch.observer/filing/0001104659-22-107408.md","text":"https://secwatch.observer/filing/0001104659-22-107408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000110465922107408/0001104659-22-107408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000110465922107408/tm2227279d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:28:21.066901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93e08166ad","claim":"Edgar B. (Chip) Cale resigned as Interim Chief Executive Officer at Passage BIO, Inc..","evidence_excerpt":"Edgar B. (Chip) Cale resigned from his position as the Company’s Interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000110465922107408/0001104659-22-107408-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"cedbac1138","claim":"William Chou was appointed as Chief Executive Officer and Director at Passage BIO, Inc..","evidence_excerpt":"the board of directors (the “Board”) of Passage Bio, Inc. (the “Company”) appointed William Chou, M.D., age 50, as (i) Chief Executive Officer and (ii) a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000110465922107408/0001104659-22-107408-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}